675 related articles for article (PubMed ID: 31914241)
21. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.
Fenaux P; Kiladjian JJ; Platzbecker U
Blood; 2019 Feb; 133(8):790-794. PubMed ID: 30602619
[TBL] [Abstract][Full Text] [Related]
22. New drugs for myeloid neoplasms with ring sideroblasts: Luspatercept vs imetelstat.
Tefferi A
Am J Hematol; 2021 Jul; 96(7):761-763. PubMed ID: 33861878
[No Abstract] [Full Text] [Related]
23. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
[TBL] [Abstract][Full Text] [Related]
24. The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia.
Delgado J; Voltz C; Stain M; Balkowiec-Iskra E; Mueller B; Wernsperger J; Malinowska I; Gisselbrecht C; Enzmann H; Pignatti F
Hemasphere; 2021 Aug; 5(8):e616. PubMed ID: 34291195
[TBL] [Abstract][Full Text] [Related]
25. Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.
Oliva EN; Platzbecker U; Garcia-Manero G; Mufti GJ; Santini V; Sekeres MA; Komrokji RS; Shetty JK; Tang D; Guo S; Liao W; Zhang G; Ha X; Ito R; Lord-Bessen J; Backstrom JT; Fenaux P
J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011768
[TBL] [Abstract][Full Text] [Related]
26. Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes.
Verma A; Suragani RN; Aluri S; Shah N; Bhagat TD; Alexander MJ; Komrokji R; Kumar R
J Clin Invest; 2020 Feb; 130(2):582-589. PubMed ID: 31961337
[TBL] [Abstract][Full Text] [Related]
27. Lowering the boom on lower-risk myelodysplastic syndromes.
Sekeres MA; Patel BJ
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):367-372. PubMed ID: 31808873
[TBL] [Abstract][Full Text] [Related]
28. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Platzbecker U; Santini V; Fenaux P; Sekeres MA; Savona MR; Madanat YF; Díez-Campelo M; Valcárcel D; Illmer T; Jonášová A; Bělohlávková P; Sherman LJ; Berry T; Dougherty S; Shah S; Xia Q; Sun L; Wan Y; Huang F; Ikin A; Navada S; Feller F; Komrokji RS; Zeidan AM
Lancet; 2024 Jan; 403(10423):249-260. PubMed ID: 38048786
[TBL] [Abstract][Full Text] [Related]
29. Development of luspatercept to treat ineffective erythropoiesis.
Kubasch AS; Fenaux P; Platzbecker U
Blood Adv; 2021 Mar; 5(5):1565-1575. PubMed ID: 33687432
[TBL] [Abstract][Full Text] [Related]
30. Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Lanino L; Restuccia F; Perego A; Ubezio M; Fattizzo B; Riva M; Consagra A; Musto P; Cilloni D; Oliva EN; Palmieri R; Poloni A; Califano C; Capodanno I; Itri F; Elena C; Fozza C; Pane F; Pelizzari AM; Breccia M; Di Bassiano F; Crisà E; Ferrero D; Giai V; Barraco D; Vaccarino A; Griguolo D; Minetto P; Quintini M; Paolini S; Sanpaolo G; Sessa M; Bocchia M; Di Renzo N; Diral E; Leuzzi L; Genua A; Guarini A; Molteni A; Nicolino B; Occhini U; Rivoli G; Bono R; Calvisi A; Castelli A; Di Bona E; Di Veroli A; Ferrara F; Fianchi L; Galimberti S; Grimaldi D; Marchetti M; Norata M; Frigeni M; Sancetta R; Selleri C; Tanasi I; Tosi P; Turrini M; Giordano L; Finelli C; Pasini P; Naldi I; Santini V; Della Porta MG;
Am J Hematol; 2023 Aug; 98(8):E204-E208. PubMed ID: 37222267
[No Abstract] [Full Text] [Related]
31. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.
Santini V; Almeida A; Giagounidis A; Gröpper S; Jonasova A; Vey N; Mufti GJ; Buckstein R; Mittelman M; Platzbecker U; Shpilberg O; Ram R; Del Cañizo C; Gattermann N; Ozawa K; Risueño A; MacBeth KJ; Zhong J; Séguy F; Hoenekopp A; Beach CL; Fenaux P
J Clin Oncol; 2016 Sep; 34(25):2988-96. PubMed ID: 27354480
[TBL] [Abstract][Full Text] [Related]
32. Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.
Platzbecker U; Santini V; Komrokji RS; Zeidan AM; Garcia-Manero G; Buckstein R; Miteva D; Keeperman K; Holot N; Nadal JA; Lai Y; Vodala S; Rosettani B; Giuseppi AC; Yucel A; Fenaux P
Leukemia; 2023 Nov; 37(11):2314-2318. PubMed ID: 37752285
[No Abstract] [Full Text] [Related]
33. Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.
Mies A; Hermine O; Platzbecker U
Curr Hematol Malig Rep; 2016 Dec; 11(6):416-424. PubMed ID: 27595736
[TBL] [Abstract][Full Text] [Related]
34. The use of luspatercept for thalassemia in adults.
Cappellini MD; Taher AT
Blood Adv; 2021 Jan; 5(1):326-333. PubMed ID: 33570654
[TBL] [Abstract][Full Text] [Related]
35. Therapy for lower-risk MDS.
Carraway HE; Saygin C
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):426-433. PubMed ID: 33275714
[TBL] [Abstract][Full Text] [Related]
36. Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts: Stimulating early and late-stage erythropoiesis.
Fattizzo B; Versino F; Bortolotti M; Rizzo L; Riva M; Barcellini W
Eur J Haematol; 2023 May; 110(5):571-574. PubMed ID: 36727250
[TBL] [Abstract][Full Text] [Related]
37. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
Park S; Kelaidi C; Meunier M; Casadevall N; Gerds AT; Platzbecker U
Ann Hematol; 2020 Jan; 99(1):7-19. PubMed ID: 31650290
[TBL] [Abstract][Full Text] [Related]
38. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Komrokji RS; Platzbecker U; Fenaux P; Zeidan AM; Garcia-Manero G; Mufti GJ; Santini V; Díez-Campelo M; Finelli C; Jurcic JG; Greenberg PL; Sekeres MA; DeZern AE; Savona MR; Shetty JK; Ito R; Zhang G; Ha X; Backstrom JT; Verma A
Leukemia; 2022 May; 36(5):1432-1435. PubMed ID: 35220402
[No Abstract] [Full Text] [Related]
39. How we manage adults with myelodysplastic syndrome.
Fenaux P; Platzbecker U; Ades L
Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
[TBL] [Abstract][Full Text] [Related]
40. Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes.
Tinsley-Vance SM; Davis M; Ajayi O
J Adv Pract Oncol; 2023 Jan; 14(1):82-87. PubMed ID: 36741213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
